Drugs.com - Pharma Industry News

Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year

FRIDAY, Jan. 14, 2025 -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without type 2 diabetes, according to a study...

Feb 15, 2025 - 00:17
 0
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
FRIDAY, Jan. 14, 2025 -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without type 2 diabetes, according to a study...
Read More

Tags:

Previous Article

Another MAGA Judge Makes Shocking Legal Argument Hoping To Catch The Attention O...

Next Article

Seroprevalence of HPAI A(H5) Identified in Bovine Veterinary Practitioners

Related Posts

Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease

Inflammatory Bowel Disease Tied to Higher Risk for Hear...

Feb 9, 2025  0

CT Exams in 2023 Projected to Result in 103,000 Future Cancers

CT Exams in 2023 Projected to Result in 103,000 Future ...

Apr 17, 2025  0

Breast Surgery Can Be Omitted After Neoadjuvant Systemic Therapy in Select Patients

Breast Surgery Can Be Omitted After Neoadjuvant Systemi...

Apr 11, 2025  0